title: Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes.
abstract: BACKGROUND
  Betatrophin is a secreted protein recently involved in β-cell replication with a potential role in type 2 diabetes mellitus (T2D).
  
  
  OBJECTIVE
  The aim of the present study was to compare the circulating concentrations of betatrophin in human obesity and T2D.
  
  
  METHODS
  Serum concentrations of betatrophin were measured by ELISA in 153 subjects: 75 obese normoglycemic subjects (OB-NG), 30 obese subjects with impaired glucose tolerance (OB-IGT), and 15 obese subjects with T2D (OB-T2D) matched by sex, age, and body adiposity, in comparison with 33 lean normoglycemic individuals (LN-NG).
  
  
  RESULTS
  Circulating levels of betatrophin were significantly decreased in obese individuals and further diminished in IGT and T2D participants (LN-NG, 45.1 ± 24.4 ng/mL; OB-NG, 26.9 ± 15.4 ng/mL; OB-IGT, 18.3 ± 10.7 ng/mL; OB-T2D, 13.5 ± 8.8 ng/mL; P < .001). A marked sexual dimorphism was found, with betatrophin levels being significantly higher in women than in men (males, 21.1 ± 16.0 ng/mL; females, 34.1 ± 20.1 ng/mL; P < .001). Interestingly, betatrophin levels were positively correlated with the quantitative insulin sensitivity check index (r = 0.46; P < .001) and with high-density lipoprotein-cholesterol concentrations (r = 0.51; P < .001).
  
  
  CONCLUSIONS
  We conclude that serum betatrophin is decreased in human obesity, being further reduced in obesity-associated insulin resistance. Betatrophin levels are closely related to obesity-associated cardiometabolic risk factors, emerging as a potential biomarker of insulin resistance and T2D.
authors: Metabolic Research Laboratory (J.G.-A., V.C., A.R., B.R., G.F.), Department of Endocrinology and Nutrition (E.P., C.S., J.S., G.F.) and Department of Biochemistry (M.J.G.), Clínica Universidad de Navarra, 31008 Pamplona, Spain; and CIBER Fisiopatología de la Obesidad y Nutrición (J.G.-A., V.C., A.R., B.R., C.S., M.J.G., J.S., G.F.), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
authors: Javier
authors: J
authors: Gómez-Ambrosi
authors: Eider
authors: E
authors: Pascual
authors: Victoria
authors: V
authors: Catalán
authors: Amaia
authors: A
authors: Rodríguez
authors: Beatriz
authors: B
authors: Ramírez
authors: Camilo
authors: C
authors: Silva
authors: María J
authors: MJ
authors: Gil
authors: Javier
authors: J
authors: Salvador
authors: Gema
authors: G
authors: Frühbeck
mesh_terms: D050154:Adiposity / Q000502:physiology; D000328:Adult; D000091306:Angiopoietin-Like Protein 8; D000075802:Angiopoietin-like Proteins; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000378:metabolism*; D005260:Female; D018149:Glucose Intolerance / Q000453:epidemiology / Q000378:metabolism*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology / Q000378:metabolism*; D036361:Peptide Hormones / Q000097:blood* / Q000172:deficiency; D012307:Risk Factors
chemical_list: C576683:ANGPTL8 protein, human; D000091306:Angiopoietin-Like Protein 8; D000075802:Angiopoietin-like Proteins; D015415:Biomarkers; D001786:Blood Glucose; D036361:Peptide Hormones